Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Parsaclisib for MCL: next steps?

Amitkumar Mehta • 9 Dec 2020
ASH 2020
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Lenalidomide Parsaclisib
CITADEL-205

Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, discusses future research based on results from the CITADEL-205 (NCT03235544) Phase II study which aimed to evaluate the efficacy and safety of parsaclisib monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients. Dr Mehta discusses the prospect of combining parsaclisib with other therapies for indolent and aggressive MCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Amitkumar Mehta

2:42
Interim results of an anti-SIRPα antibody, CC-95251, in R/R NHL
Amitkumar Mehta • 22 Dec 2021
2:57
Lymphoma highlights from ASH 2021
Amitkumar Mehta • 22 Dec 2021
3:21
CITADEL-205: Parsaclisib in R/R MCL
Amitkumar Mehta • 22 Dec 2021
3:00
Preliminary results of lemzoparlimab, an anti-CD47 antibody in R/R NHL
Amitkumar Mehta • 22 Dec 2021

Related Videos

1:24
Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi • 24 Apr 2024
2:45
The value of axi-cel as a second-line treatment in R/R LBCL
Paolo Cortesi • 24 Apr 2024
5:42
Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD
Nina Worel • 25 Apr 2024
4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals